API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

Abbott and Johnson & Johnson report positive results in coronary lithotripsy clinical trials

Abbott and Johnson & Johnson have announced successful 30-day results from separate clinical studies evaluating investigational intravascular lithotripsy (IVL) systems designed to treat calcified coronary artery disease.

Abbott’s TECTONIC study, involving 335 patients across 40 U.S. sites, evaluated the SonicForce Coronary IVL System. The trial met its primary safety and effectiveness endpoints, reporting a 0.3% target lesion failure rate and a 97% procedural success rate. The technology uses acoustic pressure waves to crack calcium buildup in narrowed heart vessels.

Johnson & Johnson’s FORWARD CAD IDE study evaluated the Shockwave Javelin Coronary IVL Catheter in a cohort of 158 patients. The study reported a 93.6% technical success rate for lesion crossing and a 93.4% freedom from major adverse cardiovascular events through 30 days. The trial focused on complex, heavily calcified lesions, with serious angiographic complications occurring in only 1.3% of patients.

Entities

Abbott · Johnson & Johnson · Shockwave Javelin Coronary IVL Catheter · SonicForce Coronary IVL System · Transcatheter Cardiovascular Therapeutics